{"id":36569,"date":"2026-08-31T12:14:37","date_gmt":"2026-08-31T06:44:37","guid":{"rendered":"https:\/\/niir.org\/blog\/?p=36569"},"modified":"2026-08-31T12:14:37","modified_gmt":"2026-08-31T06:44:37","slug":"artemisinin-manufacturing-business","status":"publish","type":"post","link":"https:\/\/www.niir.org\/blog\/artemisinin-manufacturing-business\/","title":{"rendered":"This Malaria Drug Has a Global Demand Gap That Nobody Is Filling \u2014 And India Grows the Plant It Comes From"},"content":{"rendered":"

There are few business ideas in the pharmaceutical manufacturing industry that combine domestic under-supply with global urgency like artemisinin does. This sesquiterpene lactone endoperoxide forms the core of an essential malaria treatment: the World Health Organization recommends Artemisinin-based Combination Therapies (ACTs) as the front-line treatment for Plasmodium falciparum<\/em> malaria, the deadliest strain.<\/p>\n

India is at a crucial juncture. The nation has the farming foundation and manufacturing facilities to turn into a primary participant in the manufacturing of artemisinin and its downstream derivatives globally. With the farming basis and manufacturing infrastructure, the nation could be a major player in the manufacture of artemisinin and downstream derivatives globally. However, production is divided and still reliant on imports. It’s one of the most promising business ideas today for MSME investors and entrepreneurs in the specialty pharma segment.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n